Indication: Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 In Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Sub-indication: Idiopathic Pulmonary Fibrosis (IPF)
Study Type: Drug Study
Principal Investigator: John McConnell, M.D.Norton Pulmonary Specialists
Sponsor: Sponsor: Nitto Denko Corporation
Learn more at ClinicalTrials.gov
Email for more information: NCRG@nortonhealthcare.org